Ceapro Inc. Announces Issuance of Indian Patent Application for Enabling Pressurized Gas eXpanded (PGX) Technology

Company continues to build solid IP portfolio for its unique and disruptive enabling PGX technology with protection now in the U.S., Canada, Europe and India

EDMONTON, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Office of the Controller General of Patents, Design and Trademarks, India has issued the Company Patent No. 305103 entitled, “Supercritical Fluid Treatment of High Molecular Weight Biopolymers,” related to its Pressurized Gas eXpanded (“PGX”) technology.

Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro commented, “We are delighted to receive this patent issuance from the Indian Patent Office for our novel PGX technology. India represents a very large potential market with numerous contract manufacturers in the pharmaceutical industry that we believe could benefit from our PGX technology. We continue to work towards building a robust intellectual property portfolio surrounding our unique and disruptive enabling technology and now have patent protection in the U.S., Canada, Europe and India.”

“We believe that our PGX platform technology has the potential to drive tremendous value to Ceapro in many ways. Establishing a vigorous IP portfolio around this game-changing technology enables us to successfully execute on our business development strategies by aiding in the facilitating and advancement of our discussions with potential partners, all of which is integral in progressing to our next phase of growth as a Company. Importantly, we continue to leverage our proprietary PGX technology towards the commercialization of our development projects into new products in the cosmeceutical, nutraceutical markets in the near-term and ultimately into the high-value pharmaceutical markets,” concluded Mr. Gagnon.

Ceapro is developing its PGX enabling technology at various scale levels for all industries and all applications. The Company's PGX technology is a novel spray drying technique for processing water-soluble biopolymers and can produce numerous morphologies of biopolymers ranging from fine fibers to granular powder, which are highly water soluble. Because PGX operates at lower temperatures than conventional spray drying, it also enables the incorporation of thermosensitive bioactives. The allowed patent claims cover methods related to the production, impregnation and microencapsulation of micro- and nano-particles, agglomerates and fibers from high molecular weight water-soluble biopolymers applying supercritical fluid technology utilizing PGX.

PGX processing of biopolymers results in powders with large specific surface area facilitating easier handling, dispersion, and dissolution in water much faster than powders of the same biopolymers prepared by prior art techniques, which is key to high molecular weight biopolymers especially used in cosmetic industries.

The patented PGX Technology is a platform technology that is used to convert biopolymers into high-value materials overcoming the challenges associated with the drying of high molecular weight biopolymers using conventional technologies. Applications and new chemical entities recently obtained from the use of PGX illustrate the potential to dry, purify, micronize and functionalize proteins, peptides, and polysaccharides that can lead to the development of highly potent bioactive delivery systems.

About Pressurized Gas eXpanded Liquid Technology (PGX)

The Company's patented Pressurized Gas eXpanded (PGX) is a unique and disruptive technology with several key advantages over conventional drying and purification technologies that can be used to process biopolymers into high-value, nano-sized polymer structures and novel bio-nanocomposites. PGX is ideally suited for processing challenging high-molecular-weight, water-soluble biopolymers. It has the ability to make ultra-light, highly porous polymer structures on a continuous basis, which is not possible using today's conventional technologies. PGX was invented by Dr. Feral Temelli from the Department of Agricultural, Food & Nutritional Science of the University of Alberta (U of A) along with Dr. Bernhard Seifried, now Senior Director of Engineering Research and Technology at Ceapro. The license from U of A provides Ceapro with exclusive worldwide rights in all industrial applications.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com


Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Ceapro Logo.jpg

Source: Ceapro Inc.